← Trials/Trial dossier/NCT02450253
PASTIS
CompletedPhase 2Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial
Lead sponsor
Asset
tadalafil
Listed sites
1
Recruiting sites
-
Enrollment
55
actual
Study population
Mixed / unspecified dementia
Key I/E criterion
•Age ≥55
Primary endpoint
•Deep brain blood flow
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Drug assets
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
1. Radiological evidence of cerebral small vessel disease defined as: MRI evidence of lacunar infarct(s) (≤ 1.5 cm maximum diameter) and/or confluent deep white matter leukoaraiosis (≥ grade 2 on Fazekas scale)
2. Clinical evidence of cerebral small vessel disease can be:
1. lacunar stroke syndrome with symptoms lasting >24 hours, occurring at least 6 months previously; OR:
2. transient ischaemic attack lasting < 24 hours with limb weakness, hemi-sensory loss or dysarthria at least 6 months previously AND with MRI DWI performed acutely showing lacunar infarction, OR if MRI is not performed within 10 days of TIA, a lacunar infarction in an anatomically appropriate position is demonstrated on a subsequent MRI
3. Age ≥ 55 years.
4. Imaging of the carotid arteries with Doppler ultrasound, CT angiography or MR angiography in the previous 12 months, demonstrating < 70% stenosis in both internal carotid arteries
Exclusion criteria
1. Known diagnosis of dementia
2. Cortical infarction (>1.5 cm maximum diameter)
3. Systolic BP <90 and/or diastolic BP < 50
4. Creatinine Clearance<50ml/min
5. Severe hepatic impairment
6. History of Lactose intolerance
7. Concomitant use of PDE5 inhibitors e.g. sildenafil, tadalafil, vardenafil.
8. Concomitant use of alpha-blockers e.g. alfuzosin, doxazosin, indoramin, prazosin, tamsulosin, and terazosin can all increase the risk of postural hypotension.
9. Participants receiving nicorandil and nitrates e.g. isosorbide mononitrate, isosorbide dinitrate, glyceryl trinitrate
10. weight > 130kg
11 Uncontrolled cardiac failure
12. Persistent or paroxysmal atrial fibrillation
13. History of gastric ulceration
14. History of 'sick sinus syndrome' or other supraventricular cardiac conduction conditions such as sinoatrial or atrioventricular block
15. Uncontrolled COPD
16. Stroke or TIA within the last 6 months
17. MRI not tolerated or contra-indicated : MRI exclusion criteria -Participant has a cardiac pacemaker; recent surgery; vascular clips; metal implants or joint replacements; have had metal fragments in their eyes; has ever worked on a lathe; has shrapnel from a war injury; possibility of pregnancy
18. Known monogenic causes of stroke e.g.. CADASIL
19 Unable to provide informed consent
20. enrolled in another CTIMP study
Endpoints (2)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Executive function / language
1 endpointChange in regional CBF in cortical grey matter areas Plasma [drug concentration] dependence of deep CBF as measured by MRI ASL Changes in neuropsychological parameters including attention in Neuro attention and cognitive speed
Time frame:3-5 hours following IMP dosing
change from baseline, improvement
Neuroimaging
1 endpointchange in deep brain blood flow as measured by MRI-Arterial Spin Labelling
Time frame:3-5 hours following IMP dosing
change from baseline, improvement
Publications (2)
Bibliography
Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.
Registry references + supporting bibliography
- PMID35135037via DERIVED
- PMID35080734via DERIVED
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.